Vitrolife AB · OMXSTO:VITR
Vitrolife AB — Shareholder Meeting (April 2023)
16 slides from Vitrolife AB's shareholder meeting presentation, Apr 27, 2023
Slide 1: Vitrolife logo
C27, ~ VITROLIFI 7 Lf it EXCELLENCE IN REPRODY
Slide 2: Vitrolife AB (publ) Annual General Meeting 27 April 2023
Vitrolife AB (publ) Årsstämma 27 April 2023 Jón Sigurdsson Interim CEO
Slide 3: 1 in 6 people globally is affected by infertility
1 in 6 people globally is affected by infertility Source: World Health Organization (WHO)
Slide 4: Strong underlying growth with solid drivers in the IVF market
Strong underlaying growth with solid drivers in the IVF market • Delay in motherhood Demographic & social trends • Social acceptances and awareness of IVF • Lifestyle and social changes Top 5 markets worldwide North America • Improvement in IVF lab procedures (e.g. incubation system) Technical impro
Slide 5: 2022 - A year of transformation to the Vitrolife Group
2022 - A year of transformation to the Vitrolife Group 1994 2006 2013 2014 2016 2019 2021 2022 Vitrolife was founded. The Acquisition of Acquisition of HertART Vitrolife and Igenomix Acquisition of Unisense Acquisition of Octax Acquires AI Acquisition of Igenomix first IVF-product, an ICSI Swemed La
Slide 6: Vitrolife Group at a glance
Global presence in 125 markets Employees Sales 2022 Vitrolife AB (publ) listed on ~1,100 3,234 MSEK NASDAQ Best-in-class IVF Leadership in Stockholm Large Cap medical devices reproductive portfolio genetic testing services Founded 1994 Founded 2011 6
Slide 7: Operating structure Vitrolife Group
Operating structure Vitrolife Group Executive Management and Group Functions Finance, Legal, IT, Strategy and HR & Sustainability Global Sales & Marketing Commercial excellence, Customer Services, Vitrolife Academy Media, cryo products, disposable devices and Incubation, time-lapse evaluation and la
Slide 8: Vitrolife Group vision, mission and strategy
Vitrolife Group Vision with a purpose —— Mission To fulfil the dream of To be the leading valued solution having a healthy baby. —_ provider in reproductive health and to support customers with successful _ treatment outcomes. Net debt / EBITDA 3 a Superior customer experience Sustainable structure
Slide 9: Ensuring sustainability in everything we do
Ensuring sustainability in everything we do 9
Slide 10: Full Year 2022
Full Year / 2022 10
Slide 11: Full year 2022: Strong profitable growth
Full year 2022: Strong profitable growth Sales Organic growth* 3,234 MSEK 10% +92% in SEK In local currencies EBITDA Operating cash flow 1,050 MSEK 636 MSEK Margin 32.5% (32.2% Pro forma) 11 * Pro forma: 9% Excluding Covid-19, 10% Excluding Covid-19 and divestment of GPDx business in China
Slide 12: Sales and growth per market region
Sales and growth per market region Japan Americas EMEA Asia Total Pacific 2022 growth rate (SEK) 223% 58% 52% 62% 92% Growth pro forma* (local currencies) 8% 3% 16% 19% 10% Sales (MSEK) 1,144 1,163 529 398 3,234 Share of total sales 35% 36% 16% 12% 12 * Pro forma: Excluding Covid-19
Slide 13: Key financials
Key financials Full year 2022 Full year 2021 Sales, MSEK 3,234 1,681 Gross Margin, % 55% 62% Adj. Gross Margin, %* 57% 63% Adjusted EBITDA, MSEK** 1,050 645 Adjusted EBITDA, %** 33% 38% EBITDA, MSEK 1,050 544 EBITDA Margin, % 33% 32% Earnings per share, SEK 2.91 2.97 EBITDA per share, SEK 7.75 4.75
Slide 14: Management comments
Management comments • Strong DNA of profitable growth • New structure is up and running – synergies ahead • Our combined competence enhance our value adding product offering to customers • Progress in our operational excellence work • Time-lapse is becoming standard of care in several markets • Prod
Slide 15: Our vision with a purpose: to fulfil the dream of having a healthy baby
Our vision with a purpose: to fulfil the dream of having a healthy baby 15
Slide 16: Thank you!
Thank you!